

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

26 May 2026

### The effects of Resveratrol on plasma and peripheral blood mononuclear cells (PBMCs) oxidative stress factors of type 2 diabetic patients

#### Protocol summary

##### Summary

Resveratrol, one of the phytochemicals with anti-oxidant activity, has a high potential in treatment of type 2 diabetes. The aim of this study is to investigate the effect of resveratrol on plasma and peripheral mono-nuclear cells (PBMCs) oxidative stress of the diabetic patients in a double-blind randomized clinical trial. Sixty patients with type 2 diabetes were divided into two groups randomly (30, having resveratrol, 500 mg, twice daily, morning and evening for 60 days). The 2nd group (30 patients) receives the same amount of the placebo. All patients will receive routine medication for diabetes during the study. The lack of life-threatening diseases such as cancer, infectious diseases, cardiovascular and liver diseases are of the inclusion criteria for this study. At the first and the end of the study, blood sample are taken to measure the levels of glucose, HbA1c, lipid profile, plasma oxidative stress markers such as total anti-oxidant capacity, malondialdehyde, protein carbonyl, advanced glycation end products. Furthermore, peripheral blood mononuclear cells (PBMCs) oxidative stress will be evaluated by measurement of reactive oxygen species (ROS), glutathione and the expression of SIRT1 and MnSOD and RAGE.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2015072523336N1**  
Registration date: **2015-08-19, 1394/05/28**  
Registration timing: **prospective**

Last update:

Update count: **0**

##### Registration date

2015-08-19, 1394/05/28

#### Registrant information

##### Name

Reza Meshkani

##### Name of organization / entity

Department of Biochemistry, Faculty of Medicine,  
Tehran University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8895 3004

##### Email address

rmeshkani@sina.tums.ac.ir

#### Recruitment status

##### Recruitment complete

#### Funding source

Vice Chancellor of Research, Tehran University of Medical Sciences, Dr. Masoud Younesian. Diabetes Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences

#### Expected recruitment start date

2015-09-23, 1394/07/01

#### Expected recruitment end date

2016-09-22, 1395/07/01

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### Scientific title

The effects of Resveratrol on plasma and peripheral blood mononuclear cells (PBMCs) oxidative stress factors of type 2 diabetic patients

#### Public title

The effect of resveratrol on diabetes treatment

#### Purpose

Treatment

#### Inclusion/Exclusion criteria

Inclusion criteria: Ability to give informed consent; Age 40-60 years; Diabetic patients with BMI less than 35 kg/m<sup>2</sup>; Lack of insulin therapy; HbA1c > 7.5. Exclusion criteria: Subjects on any antioxidant medication; Patient on non-steroidal anti-inflammatory drug; Patients on insulin therapy; Patients with severe diabetic complications such as nephropathy, retinopathy and amputation; On any agent with significant antioxidant properties; History of alcohol abuse; Any life threatening disease such as cancer and infectious diseases; Allergy to peanuts, grapes, wine, mulberries; Pregnant women; Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass surgery or coronary angioplasty) in the previous four weeks; Subjects on anticoagulants; History of recent taking red grapes, pistachios, almonds and berries; ALT and/or AST > 2 times above upper limit of normal.

**Age**

From **40 years** old to **60 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description****Blinding (investigator's opinion)**

Double blinded

**Blinding description****Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

The Ethics Committee of Tehran University of Medical Sciences

**Street address**

Tehran University of Medical Sciences, Poursina avenue,

**City**

Tehran

**Postal code****Approval date**

2015-07-20, 1394/04/29

**Ethics committee reference number**

IR.TUMS.REC.1394.389

**Health conditions studied****1****Description of health condition studied**

Type 2 diabetes

**ICD-10 code**

E11

**ICD-10 code description**

Non-insulin-dependent diabetes mellitus

**Primary outcomes****1****Description**

HbA1c

**Timepoint**

Before and two months after intervention

**Method of measurement**

HPLC

**2****Description**

FBS

**Timepoint**

Before and two months after intervention

**Method of measurement**

Enzymatic reaction

**3****Description**

Reactive oxygen species (ROS)

**Timepoint**

Before and two months after intervention

**Method of measurement**

Flow cytometry

**Secondary outcomes****1****Description**

HDL

**Timepoint**

Before and two months after intervention

**Method of measurement**

Spectrophotometry

**2****Description**

LDL

**Timepoint**

Before and two months after intervention

**Method of measurement**

Spectrophotometry

### 3

**Description**

Insulin

**Timepoint**

Before and two months after intervention

**Method of measurement**

ELISA Kit

### 4

**Description**

Cholesterol

**Timepoint**

Before and two months after intervention

**Method of measurement**

Spectrophotometry

### 5

**Description**

Triglyceride

**Timepoint**

Before and two months after intervention

**Method of measurement**

Spectrophotometry

### 6

**Description**

ALT

**Timepoint**

Before and two months after intervention

**Method of measurement**

Spectrophotometry

### 7

**Description**

AST

**Timepoint**

Before and two months after intervention

**Method of measurement**

Spectrophotometry

### 8

**Description**

Insulin resistance

**Timepoint**

Before and two months after intervention

**Method of measurement**

HOMA-IR

### 9

**Description**

CRP

**Timepoint**

Before and two months after intervention

**Method of measurement**

ELISA Kit

### 10

**Description**

Creatinine

**Timepoint**

Before and two months after intervention

**Method of measurement**

Spectrophotometry

### 11

**Description**

Urea

**Timepoint**

Before and two months after intervention

**Method of measurement**

Spectrophotometry

### 12

**Description**

BMI

**Timepoint**

Before and two months after intervention

**Method of measurement**

the formula for BMI is weight in kilograms divided by height in meters squared

### 13

**Description**

Diastolic and systolic blood pressure

**Timepoint**

Before and two months after intervention

**Method of measurement**

Sphygmomanometer and Stethoscope will be used to measure the blood pressure

### 14

**Description**

Glutathione

**Timepoint**

Before and two months after intervention

**Method of measurement**

Spectrophotometry

### 15

**Description**

Malondialdehyde (MDA)

**Timepoint**

Before and two months after intervention

**Method of measurement**

Spectrophotometry

### 16

**Description**

Plasma protein carbonyl

**Timepoint**

Before and two months after intervention

**Method of measurement**

Spectrophotometry

## 17

### **Description**

Total antioxidant capacity

### **Timepoint**

Before and two months after intervention

### **Method of measurement**

Spectrophotometry

## 18

### **Description**

Expression of Sirt1

### **Timepoint**

Before and two months after intervention

### **Method of measurement**

Real-time PCR

## 19

### **Description**

Expression of MnSOD

### **Timepoint**

Before and two months after intervention

### **Method of measurement**

Real-time PCR

## 20

### **Description**

Expression of RAGE

### **Timepoint**

Before and two months after intervention

### **Method of measurement**

Real-time PCR

## **Intervention groups**

### 1

#### **Description**

Resveratrol, 500 mg, twice daily, morning and evening for 60 days

#### **Category**

Treatment - Drugs

### 2

#### **Description**

Placebo, 500 mg, twice daily, morning and evening for 60 days

#### **Category**

Placebo

## **Recruitment centers**

### 1

#### **Recruitment center**

##### **Name of recruitment center**

Diabetes Research Center, Endocrinology and Metabolism Research Institute

##### **Full name of responsible person**

Dr Ensi Nasli Esfahani

##### **Street address**

Clinic of Diabetes, West 17 Shahrivar, North Kargar Ave, Amir Abad

##### **City**

Tehran

## **Sponsors / Funding sources**

### 1

#### **Sponsor**

##### **Name of organization / entity**

Vice chancellor of Research, Tehran University of Medical Sciences

##### **Full name of responsible person**

Dr. Masoud Younesian

##### **Street address**

Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Poursina avenue

##### **City**

Tehran

##### **Grant name**

##### **Grant code / Reference number**

##### **Is the source of funding the same sponsor organization/entity?**

Yes

##### **Title of funding source**

Vice chancellor of Research, Tehran University of Medical Sciences

##### **Proportion provided by this source**

##### **Public or private sector**

*empty*

##### **Domestic or foreign origin**

*empty*

##### **Category of foreign source of funding**

*empty*

##### **Country of origin**

##### **Type of organization providing the funding**

*empty*

### 2

#### **Sponsor**

##### **Name of organization / entity**

Diabetes Research Center, Endocrinology and Metabolism research Institute, Tehran University of Medi

##### **Full name of responsible person**

Dr. Ensi Nasli Esfahani

##### **Street address**

Clinic of Diabetes, No 17, West Shahrivar, North Kargar Avenue, Amir Abad, Tehran

##### **City**

Tehran

##### **Grant name**

##### **Grant code / Reference number**

##### **Is the source of funding the same sponsor organization/entity?**

Yes

##### **Title of funding source**

Diabetes Research Center, Endocrinology and  
Metabolism research Institute, Tehran University of Medi

**Proportion provided by this source**

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

*empty*

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Shadi Seyyed Ebrahimi

**Position**

PhD Student of Clinical Biochemistry

**Other areas of specialty/work**

**Street address**

Tehran University of Medical Sciences, Poursina  
avenue

**City**

Tehran

**Postal code**

**Phone**

+98 21 8895 3004

**Fax**

**Email**

shadi\_seyyedebrahimi@yahoo.com

**Web page address**

**Person responsible for scientific  
inquiries**

**Contact**

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Dr. Reza Meshkani

**Position**

PhD, Clinical Biochemistry

**Other areas of specialty/work**

**Street address**

Tehran University of Medical Sciences, Poursina

avenue

**City**

Tehran

**Postal code**

**Phone**

+98 21 8895 3004

**Fax**

**Email**

rmeshkani@sina.tums.ac.ir

**Web page address**

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Shadi Seyyed Ebrahimi

**Position**

PhD Student of Clinical Biochemistry

**Other areas of specialty/work**

**Street address**

Tehran University of Medical Sciences, Poursina  
avenue,

**City**

Tehran

**Postal code**

**Phone**

+92 1889 53004

**Fax**

**Email**

shadi\_seyyedebrahimi@yahoo.com

**Web page address**

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*